Pharmexa granted U.S. patent for anti-cancer vaccine GV1003

By Lisa Kerner

Charlotte, N.C., Sept. 8 - Pharmexa A/S has been granted a broad U.S. patent for GV1003, its new peptide vaccine candidate aimed at the telomerase enzyme affecting cancer cells' ability to divide.

In addition, the pharmaceutical company received a notice of allowance from the European patent authorities, with patent issuance expected shortly.

Pharmexa, located in Horsholm, Denmark, is investigating GV1003 as a universal cancer vaccine in preclinical studies, both independently and in conjunction with Karolinska University Hospital in Sweden.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.